Skip to main content
SpringerLink
Log in

Tumour molecular classification-guided treatment cost effective for stage I or II high-risk EC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Orellana TJ, et al. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer. Gynecologic Oncology : 2 Nov 2021. Available from: URL: http://doi.org/10.1016/j.ygyno.2021.10.071

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tumour molecular classification-guided treatment cost effective for stage I or II high-risk EC. PharmacoEcon Outcomes News 891, 27 (2021). https://doi.org/10.1007/s40274-021-08185-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08185-7

Search

Navigation